Homepage
Education
This accredited activity will help clinicians understand the prevalence of TD, recognize the risk factors, and introduce effective screening tools.
This accredited activity explores when to treat TD, and reviews some strategies that are not effective for managing TD and should be avoided.
These accredited videos discuss the role of VMAT2 inhibitors as the preferred treatment for tardive dyskinesia (TD), highlighting their mechanisms of action and differences in metabolism, as well as reviewing practical concerns around use and reviewing FDA-approval status.
View these accredited, narrated videos on deutetrabenazine and valbenazine, providing an overview of their dose-response relationships, highlighting their efficacy in managing tardive dyskinesia, and examining the safety profiles established through clinical studies.
News
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms. Researchers reported their findings in a poster presented at Psych Congress.
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. The drug, formerly known as KarXT, is the first new pharmacological treatment approved for schizophrenia in over 30 years.
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient Reported Outcomes.
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the US Food and Drug Administration (FDA), providing an alternate medication option for adults with tardive dyskinesia (TD) and chorea associated with Huntington disease.
Navigating treatment decisions for tardive dyskinesia involves more than just relying on the AIMS scale.
Videos
This animated video visually explores the distinct mechanisms of action (MOAs) of anticholinergics and VMAT-2 inhibitors in managing tardive dyskinesia. It highlights the efficacy and safety differences between the two drug classes, emphasizing how VMAT-2 inhibitors target dopamine dysregulation at the synaptic level, resulting in more targeted and effective symptom relief compared to the broader and less specific effects of anticholinergics.
This video series offers guidance on performing the Abnormal Involuntary Movement Scale (AIMS) exam, a standardized tool for assessing tardive dyskinesia and other movement disorders. The videos include visual representations of the severity levels for each assessment, helping healthcare providers accurately evaluate and document involuntary movements.
This video showcases comparisons of patients with tardive dyskinesia (TD) before and after treatment, highlighting the visible improvements in involuntary movements. Through real-life examples, it demonstrates how treatment can significantly enhance patients' quality of life.
In this instructional video, Psych Congress co-chair Rakesh Jain, MD, MPH, explains the importance of the Abnormal Involuntary Movement Scale (AIMS) exam in the diagnosis and monitoring of patients with tardive dyskinesia. Dr. Jain reviews the components of the AIMS and runs through the steps for conducting the exam, illustrated with clips of a patient (portrayed by an actor) to show the various activation techniques.
As an April 2023 article published in The Journal of Clinical Psychiatry concluded, “Tardive dyskinesia imposes a substantial burden on patients’ physical, psychological, social, and professional lives and impacts management of their underlying condition.”
Posters
Tardive dyskinesia (TD) is a hyperkinetic movement disorder resulting from chronic exposure to antipsychotics. TD is underdiagnosed; understanding barriers to diagnosis is an unmet need. We aimed to understand patient perspectives on barriers to and determinants of TD diagnosis.
There is limited understanding of how tardive dyskinesia (TD) affects individuals with different underlying psychiatric conditions.
Once-daily valbenazine is approved for tardive dyskinesia (TD) and Huntington’s disease (HD) chorea. Dysphagia is common in both disorders, and alternative modes for oral medication administration are available with 2 approved valbenazine formulations.
Valbenazine is a once-daily medication approved for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington’s disease. Data from a 48-week, open-label study of valbenazine in patients with TD (KINECT 4 [NCT02405091]) were analyzed to assess a potential threshold for remission of TD while taking valbenazine.
Tardive dyskinesia (TD) can profoundly impact patients’ daily functioning and overall quality of life, making appropriate diagnosis and management critical. This study aimed to identify changes in practice patterns, knowledge, and barriers among United States (US) psychiatry clinicians in managing patients with TD over time and to determine how continuing medical education (CME) has impacted clinicians' adherence to guideline- and evidence-based care.